Skip to main content
. Author manuscript; available in PMC: 2007 Mar 19.
Published in final edited form as: Pharmacol Ther. 2005 Jun;106(3):357–387. doi: 10.1016/j.pharmthera.2005.01.001

Table 7.

FMO activities not involving S- or N-oxygenation

Substrate Product FMO Km (μM) Reference
Carbon
5,6-Dimethylxanthenone-4-acetic acid 6-Methyl hydroxyl hFMO3a Zhou et al., 2002
Salicylaldehyde Pyrocatechol/formate pFMO1 500–600 Chen et al., 1995
Selenium
Benzeneselenol pFMO1 18 Ziegler et al., 1992
Benzylselenide pFMO1 0.7 Chen & Ziegler, 1994
Dimethylselenide Selenoxide pFMO1 Goeger & Ganther, 1994
Methylphenylselenide Selenoxide pFMO1 0.3 Chen & Ziegler, 1994
2-(Methylseleno)benanilide Selenoxide pFMO1 5 Ziegler et al., 1992
2-(Methylseleno)cinnamonitrile pFMO1 3 Ziegler et al., 1992
N-[2-(methylseleno)ethyl]benzamide pFMO1 1 Ziegler et al., 1992
Phenylselenomethyl)trimethylsilane pFMO1 10 Ziegler et al., 1992
2-Selenylbenzanilide pFMO1 Chen & Ziegler, 1994
Selenocyteine Se-conjugates Selenoxide pFMO1 Rooseboom et al., 2001
Selenourea pFMO1 3 Ziegler et al., 1992
Others
Diphenylmethylphosphine Oxide pFMO1 Smyser & Hodgson, 1985
Boronic acids pFMO1 Jones & Ballou, 1986
Iodine pFMO1 Ziegler et al., 1980
a

p = pig; h = human.